Zobrazeno 1 - 10 of 16 pro vyhledávání: '"M T, Schreeder"'
1
A phase I trial of pan-Bcl-2 antagonist obatoclax administered as a 3-h or a 24-h infusion in combination with carboplatin and etoposide in patients with extensive-stage small cell lung cancer
Autor: M. M. Moezi, J. Schnyder, Alberto Chiappori, M S Berger, M. T. Schreeder, J. Stephenson, Deepa S. Subramaniam, J. L. Blakely, Ravi Salgia, Helen J. Ross, Q. S. Chu
Publikováno v: British Journal of Cancer
British journal of cancer, vol 106, iss 5
Background: Bcl-2 family genes are frequently amplified in small cell lung cancer (SCLC). A phase I trial was conducted to evaluate the safety of obatoclax, a Bcl-2 family inhibitor, given in combination with standard chemotherapy. Methods: Eligible
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::6ebf36639932bdc837e3b7f5dbf3ab21
https://pubmed.ncbi.nlm.nih.gov/22333598
Zobrazit plný text záznamu
2
Carcinoma of unknown primary site
Autor: F A, Greco, H A, Burris, J B, Erland, J R, Gray, L A, Kalman, M T, Schreeder, J D, Hainsworth
Publikováno v: Cancer. 89(12)
The long term survival and toxicity associated with the chemotherapy combination of paclitaxel, carboplatin, and extended-schedule etoposide used for the treatment of patients with metastatic carcinoma of unknown primary site were evaluated.Seventy-o
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=pmid________::11d17a7925fafd190881787bd13c056f
https://pubmed.ncbi.nlm.nih.gov/11135228
Zobrazit plný text záznamu
5
A phase Ib trial of Bcl-2 inhibitor obatoclax in combination with carboplatin and etoposide for previously untreated patients with extensive-stage small cell lung cancer (ES-SCLC)
Autor: M. T. Schreeder, Q. S. Chu, M. M. Moezi, M. M. Modiano, Shakun Malik, J. L. Blakely, Alberto Chiappori, Ravi Salgia, J. Stephenson, M. S. Berger
Publikováno v: Journal of Clinical Oncology. 27:3576-3576
3576 Background: Obatoclax (Ob) is a small-molecule antagonist of all the Bcl-2 prosurvival proteins. In vitro it enhances the effects of the drugs cisplatin and etoposide. Bcl-2 family proteins are frequently expressed in SCLC, and SCLC cell lines a
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::057471dd6b25f2f67c47aa9fef627e94
https://doi.org/10.1200/jco.2009.27.15_suppl.3576
Zobrazit plný text záznamu
7
TLE3 as a biomarker for taxane sensitivity in breast cancer
Autor: Rodney A. Beck, Brian Z. Ring, Noel C Estopinal, N. Watroba, David G. Hicks, Robert S. Seitz, Christine Murekeyisoni, Swati Kulkarni, M. T. Schreeder, Douglas T. Ross
Publikováno v: Journal of Clinical Oncology. 26:573-573
573 Background: The addition of taxanes (T) to chemotherapeutic regimens has not demonstrated a consistent therapeutic benefit in early stage breast cancer (Ward, HTA 2007). A recent study by Hayes, et al. suggested that HER2+ breast tumors may gain
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::59633b9084ea6ab672ed0eba49b6197b
https://doi.org/10.1200/jco.2008.26.15_suppl.573
Zobrazit plný text záznamu
8
Phase I report from a multicenter trial of perifosine (PERI) + sunitinib (SUT) in patients with advanced cancers including renal cell carcinoma (RCC)
Autor: B. Ebrahimi, L. Gardner, Peter Sportelli, Robert Birch, S. P. Chawla, J. P. Allerton, P. Kaiser, I. C. Henderson, M. T. Schreeder
Publikováno v: Journal of Clinical Oncology. 26:14565-14565
14565 Background: PERI is an oral alkylphosphocholine that affects multiple signaling pathways, most importantly Akt, and is active in multiple tumor types including sarcoma and RCC. In a phase II trial, 6/9 (66%) RCC patients (pts) derived clinical
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::faee34ffea82e074b574597412c1fd71
https://doi.org/10.1200/jco.2008.26.15_suppl.14565
Zobrazit plný text záznamu
9
Mucormycosis: a community hospital perspective
Autor: L F, Harris, J K, Hon, M T, Schreeder
Publikováno v: Alabama medicine : journal of the Medical Association of the State of Alabama. 60(1-2)
Mucormycosis (synonymous with phycomycosis and zygomycosis) is a devastating fungal infection which usually involves patients with diabetes mellitus, often complicated by ketoacidosis, and malignant neoplasms, commonly leukemia and lymphoma. Clinical
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=pmid________::e9be7a289054f7521f6ebbc377a937e3
https://pubmed.ncbi.nlm.nih.gov/2239627
Zobrazit plný text záznamu
10
Perifosine (P), active as a single agent for renal cell carcinoma (RCC), now in phase I trials combined with tyrosine kinase inhibitors (TKI)
Autor: M. T. Schreeder, Robert Birch, J. Hargis, J. Waples, L. T. Campos, J. Stephenson, I. C. Henderson
Publikováno v: Journal of Clinical Oncology. 25:15622-15622
15622 Background: P is an oral alkylphosphocholine with effects on multiple pathways including Akt, MAPK and JNK. Akt/S6 is often activated in RCC and associated with resistance. In a phase I study of P, 3/6 RCC patients (pts) had stable disease (SD)
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::c342314ad51bdf5fb22b5d6eb43328ee
https://doi.org/10.1200/jco.2007.25.18_suppl.15622
Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání

Omezení vyhledávání
Plný text Recenzováno Digitální knihovna AV ČR
Zdroje